Journal of Dermatological Treatment · 2024 · 10 citations · 18 references
Life SciencesImmunologyPharmacotherapyClinical ImmunologyImmunotherapyRheumatologyAutoimmune DiseasesImmune-mediated Inflammatory DiseasesInflammatory Skin DiseasesInflammatory Skin DisordersPsoriatic ArthritisTreatment Response MonitoringCharlson Comorbidity IndexCohort Study InvestigationMonitoring Treatment ResponsePsoriasis Follow-upPsoriasis TherapyPsoriatic Disease
BACKGROUND: Data on the characteristics and treatment outcomes of super-responders and non-super-responders in psoriasis under adalimumab treatment are limited. METHODS: A retrospective analysis from psoriatic patients treated with adalimumab was compared to characterize super-responders vs non-super-responders' groups, identify factors associated with super response, and assess treatment outcomes after switching. RESULTS: 15 out of 70 (21.4%) patients were categorized as super-responder. The proportion of patients achieving a PASI 100 response was significantly higher in super-responders than non-super-responders at weeks 12, 24, and 52. Female sex and Charlson Co-morbidity Index were significantly associated with super-responders. A high level of high-density lipoprotein was independently associated with PASI 90 response at weeks 24 and 52. Additionally, nearly 35%-43% of non-super-responders switching to interleukin-17A (IL-17A) inhibitors may achieve a PASI 100 response at week 12. In contrast, all super-responders switching to IL-17A inhibitors achieved a PASI 100 response at week 4. CONCLUSIONS: Super-responders treated with adalimumab have a higher rate of being female and fewer comorbidities. And super-responders have better PASI responses than non-super-responders, whether the patients were treated with adalimumab or switched to IL-17A inhibitors.
18
The metabolic syndrome—a new worldwide definition
K. G. M. M. Alberti, Paul Zimmet, Jonathan E. Shaw · The Lancet · 2005 · 9.3K citations
Florence Dalgard, Uwe Gieler, Lucía Tomás Aragonés et al. · Journal of Investigative Dermatology · 2014 · 961 citations · Full text
Kenneth B. Gordon, Richard G. Langley, Craig L. Leonardi et al. · Journal of the American Academy of Dermatology · 2006 · 507 citations
Medicine, Dermatology, Immunology +10
Richard B. Warren, Catherine Smith, Zenas Z N Yiu et al. · Journal of Investigative Dermatology · 2015 · 369 citations